Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims

1.   (Currently Amended) A method to elicit an immune response against influenza in a subject, which method comprises administering to said subject an amount of influenza vaccine effective to elicit said response;

wherein said influenza vaccine comprises at least one influenza hemagglutinin (HA) antigen formulated with proteosomes in the substantial absence of detergent, and wherein the formulation ratio of proteosomes to influenza HA antigen is between 2:1 ~~or greater~~ and 8:1.

2.   (Original) The method of claim 1 wherein the subject is human.

3.   (Original) The method of claim 1 wherein said administering is by an intranasal route.

4.   (Original) The method of claim 1 wherein said administering is by a parenteral route.

5.   (Original) The method of claim 1 wherein said administering is by an intramuscular injection.

6.   (Original) The method of claim 1 wherein said vaccine is multivalent.

7.   (Previously Presented) The method of claim 1 wherein said vaccine comprises at least two influenza HA antigens.

8. (Currently Amended) A method for treating infection in a subject comprising administering to the subject in need thereof an influenza vaccine prepared by a method which comprises:

providing a mixture of at least one influenza hemagglutinin (HA) antigen with a proteosome preparation in the presence of detergent, wherein the ratio of proteosomes to antigen is between 2:1 ~~or greater~~ and 8:1;

removing detergent from said mixture by diafiltration or ultrafiltration to obtain a proteosome-HA composition, and

formulating said composition into a vaccine.

9. – 11. (Cancelled)

12. (Currently Amended) A method for treating an influenza infection in a subject in need thereof, comprising administering to the subject a composition effective in shifting an immune response against the influenza infection from a Type 2 response toward a Type 1 response, which composition is prepared by a method which comprises:

providing a mixture of at least one influenza hemagglutinin (HA) antigen with a proteosome preparation in the presence of detergent wherein the ratio of proteosomes to HA is between 2:1 ~~or greater~~ and 8:1; and

removing detergent from said mixture by diafiltration or ultrafiltration to obtain a proteosome-HA composition.

13. (Previously Presented) The method according to either 8 or claim 12 wherein the subject is a human.

14. (Previously Presented) The method according to any one of claims 1, 8, and 12 wherein the subject is a non-human animal.

15. (Previously Presented) The method according to any one of claims 1, 8 and 12 wherein the ratio of proteosomes to HA antigen is 2:1.

16.   (Previously Presented) The method according to any one of claims 1, 8 and 12 wherein the ratio of proteosomes to HA antigen is 4:1.

17.   (Previously Presented) The method according to claim 8 wherein the vaccine comprises at least two HA antigens.

18.   (Previously Presented) The method according to either claim 1 or claim 8 wherein the vaccine comprises at least three HA antigens.

19.   (Previously Presented) The method according to claim 12 wherein the composition comprises at least two HA antigens or comprises at least three HA antigens.

20.   (Previously Presented) The method according to claim 8 wherein the vaccine is administered by an intranasal route, a parenteral route, or by an intramuscular injection.

21.   (Currently Amended) The method according to claim 1 wherein the influenza vaccine is prepared by a method comprising (a) providing a mixture of the influenza HA antigen with a proteosome preparation in the presence of detergent wherein the ratio of proteosomes to HA antigen is between 2:1 ~~or greater~~ and 8:1; (b) removing the detergent from the mixture by diafiltration or ultrafiltration to obtain a proteosome-HA antigen composition; and (c) formulating the composition into an influenza vaccine.